Regulatory T cells (Tregs) are central in controlling adaptive immunity. The importance of Tregs in preventing autoimmunity has been demonstrated both in experimental models and in patients with mutations in the essential transcription factor Foxp3 (1). This has now been translated to strategies that can exploit this capacity in clinical settings, including either strategies to control Treg numbers in vivo or through ex vivo expansion and adoptive transfer (2).
Diseases that are prime candidates for Treg-mediated immunoregulation include different forms of autoimmunity and organ transplantation. The latter condition is complicated by the fact that transplant recipients are dependent on continuous and lifelong systemic immunosuppressive medication. Therefore, any form of immunotherapy making use of Tregs should be considered in the context of these drugs. Calcineurin inhibitors (CNI), including cyclosporine and tacrolimus, are the cornerstone of current immunosuppressive regimens, and have been shown to actively interfere with T-cell activation and function, including the function of Tregs. In PNAS, Whitehouse et al. (3) investigate in detail the interaction between Tregs and CNI, and demonstrate that-specifically in Tregs-low-dose IL-2 has the potential to overcome this inhibitory effect of CNI (Fig. 1) .
At first glance the choice of IL-2 may be surprising, because IL-2 is well known as a T-cell growth factor and is clinically used as an immunostimulatory molecule in patients with cancer. However, Tregs are characterized by constitutive high expression of CD25, a component of the IL-2R complex, generating a high-affinity receptor. As a consequence, Tregs can respond to much lower concentrations of IL-2 compared with effector CD4 and CD8 T cells, or NK cells. Moreover, activation of Tregs seems to be exclusively dependent on IL-2, whereas other effector T cells can also be activated by other members of the IL-2 family, including IL-7. As a consequence, deficiencies in IL-2 or IL-2R signaling are associated with autoimmunity rather than with immunodeficiency, which is also known as the IL-2 paradox (4).
The Whitehouse et al. report (3) shows that both liver and kidney transplant recipients who are on CNI therapy have a lower frequency of Tregs. This is especially true for CD45RA − FoxP3 hi Treg, a subset previously described to have strong suppressive capacity (5). In addition, patients on CNI were shown to have lower serum IL-2, reduced IL-2 production upon activation, and reduced expression of CD25 on this CD45RA
− FoxP3 hi population. This is not compensated by increased expression of CD127, a component of the IL-7R.
In vitro experiments are used to investigate the relationship between CNI and different concentrations of IL-2 or IL-7. As expected from the differential effects on CD25 and CD127 expression, the Foxp3 hi population could only be rescued by IL-2. Similar results could be confirmed in vivo in mice, where 7-d treatment with CNI reduced circulating numbers of Tregs, which also could be rescued by IL-2 therapy in vivo. Moreover, Tregs isolated from mice following IL-2 therapy showed a stronger suppressive capacity.
CNI interfere with T-cell activation through nuclear factor of activated T-cells (NFAT) translocation prevention. Image stream analysis showed that, already under steady-state conditions, Tregs have more translocated NFAT in the nucleus, and the activation-induced translocation in Tregs is less sensitive for CNI inhibition. Importantly, the clinical potential of these findings is demonstrated in two experimental models of allogeneic skin transplantation, where prolonged graft survival is observed by combining CNI and IL-2 therapy. In one model, IL-2 was administered in the last week of a 4-wk CNI-treatment protocol, and was shown to prolong graft survival after cessation of immunosuppressive medication. Under these conditions, increasing numbers of Tregs could be demonstrated both within the graft and in graft-draining lymph nodes (3).
Based on the results described in the Whitehouse et al. report (3), it would be interesting to translate these findings toward clinical transplantation. Low-dose IL-2 therapy has been applied in the clinical setting, specifically in conditions of autoimmunity, including hepatitis C virus-induced vasculitis (6), type 1 diabetes (7), and systemic lupus erythematosus (8) . In these cases, therapy appeared safe and was characterized by an increase in circulating Tregs. Even more, low-dose IL-2 therapy has also been used in bone marrow transplant recipients with graft-versus-host disease, of which a large proportion had received CNI (9) .
However, there are still hurdles to overcome before bringing this to the transplant clinic. As mentioned, IL-2 is best known for its clinical application in tumor therapy, where original high doses were associated with severe complications. This finding implies that a well-controlled and individualized protocol of dosing might be required, and asks for biomarkers to identify "low-dose" IL-2 (10). Interestingly, a recent study applied mass cytometry to provide an unprecedented insight into IL-2 responsiveness of 18 different lymphocyte subsets (11) .
Another complication is the fact that blocking anti-CD25 antibodies has been shown to be beneficial as induction therapy in the peri-operative period of the transplantation procedure and to reduce acute rejection rates. This finding goes together with the need for strong immunosuppressive therapy in the early posttransplant period, consisting of triple therapy, including CNI. However, it has become apparent that this high level of immunosuppression comes at the price of major longterm side effects, including development of malignancies, infections, and cardiovascular complications. Therefore, there is an unmet medical need to safely taper or withdraw part of the immunosuppressive medication. One opportunity might be the use of regulatory cell populations, including Tregs, regulatory dendritic cells, or mesenchymal stromal cells (12, 13) . Interestingly, another immunosuppressive drug, rapamycin, has been used for more selective ex vivo expansion of Tregs, as well as for combined administration with Tregs in vivo (2, 14). The Whitehouse et al. paper (3) describes the rationale of how the number and function of regulatory T cells can be increased in vivo, even under an umbrella of CNI treatment.
